Clinically, anti-inflammatory and immunosuppressive small-molecule drugs, including systemic corticosteroids, the tumor necrosis factor-α (TNF-α) inhibitor infliximab, and amino salicylic acid, are common approaches for the treatment of IBD 4. This evidence concerns the gene TNF and inflammatory bowel disease.